Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (Layersomes)

Molecular Pharmaceutics

Volumn 9, Issue 9, 2012, Pages 2626-2635

  Jain, Sanyog ^a   Patil, Swapnil R ^a   Swarnakar, Nitin K ^a   Agrawal, Ashish K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

cardiotoxicity; doxorubicin; layersomes; liposomes; oral delivery; polyelectrolytes

Indexed keywords

CREATINE KINASE MB; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; LAYERSOME; LIPOSOME; MALONALDEHYDE; OCTADECYLAMINE; POLYACRYLIC ACID; POLYELECTROLYTE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; KINETICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SUSTAINED DRUG RELEASE;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; ANIONS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CATIONS; CREATINE KINASE; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ELECTROLYTES; FEMALE; GLUTATHIONE; L-LACTATE DEHYDROGENASE; LIPOSOMES; MALONDIALDEHYDE; PARTICLE SIZE; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84865974128     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300202c     Document Type: Article

References (27)

1. Travis, L. B.; Curtis, R. E.; Boice, J. D., Jr; Hankey, B. F.; Fraumeni, J. F., Jr Second cancers following non-Hodgkins lymphoma Cancer 1991, 67 (7) 2002-2009
2. Beijnen, J. H.; Van der Houwen, O.; Underberg, W. J. M. Aspects of the degradation kinetics of doxorubicin in aqueous solution Int. J. Pharm. 1986, 32 (2-3) 123-131 (Pubitemid 16015291)
3. Jain, A. K.; Swarnakar, N. K.; Das, M.; Godugu, C.; Singh, R. P.; Rao, P. R.; Jain, S. Augmented anticancer efficacy of doxorubicin loaded polymeric nanoparticles after oral administration in breast cancer induced animal model Mol. Pharmaceutics 2011, 8 (4) 1140-1151
4. Perez, A. T.; Domenech, G. H.; Frankel, C.; Vogel, C. L. Pegylated Liposomal Doxorubicin (Doxil) for Metastatic Breast Cancer Cancer Invest. 2002, 20 (S2) 22-29
5. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers Nature Rev. Drug Discovery 2005, 4 (2) 145-160 (Pubitemid 40282557)
6. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 2004, 56 (2) 185-229 (Pubitemid 38720829)
7. OBrien, M. E. R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 2004, 15 (3) 440-449 (Pubitemid 38444547)
8. Jain, A. K.; Das, M.; Swarnakar, N. K.; Jain, S. Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics Crit. Rev. Ther. Drug. Carrier Syst. 2011, 28 (1) 1-45
9. Ke, W.; Zhao, Y.; Huang, R.; Jiang, C.; Pei, Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system J. Pharm. Sci. 2008, 97 (6) 2208-2216
10. Benival, D. M.; Devarajan, P. V. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability Int. J. Pharm. 2011, 423 (2) 554-561
11. Choi, J. S.; Piao, Y. J.; Kang, K. W. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin Arch. Pharm. Res. 2011, 34 (4) 607-613
12. Sonneveld, P.; Suciu, S.; Weijermans, P.; Beksac, M.; Neuwirtova, R.; Solbu, G.; Lokhorst, H.; Van Der Lelie, J.; Dohner, H.; Gerhartz, H. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914) Br. J. Hamaetol. 2001, 115 (4) 895-902 (Pubitemid 34044154)
13. Kalaria, D. R.; Sharma, G.; Beniwal, V.; Ravi Kumar, M. N. V. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats Pharm. Res. 2009, 26 (3) 492-501
14. Rowland, R. N.; Woodley, J. F. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase Biochim. Biophys. Acta 1980, 620 (3) 400-409
15. Chen, H.; Torchilin, V.; Langer, R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers Pharm. Res. 1996, 13 (9) 1378-1383 (Pubitemid 26344985)
16. Wu, Z. H.; Ping, Q. N.; Wei, Y.; Lai, J. M. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice Acta Pharm. Sin. 2004, 25 (7) 966-972 (Pubitemid 38915458)
17. Taira, M. C.; Chiaramoni, N. S.; Pecuch, K. M.; Alonso-Romanowski, S. Stability of liposomal formulations in physiological conditions for oral drug delivery Drug Delivery 2004, 11 (2) 123-128 (Pubitemid 38437081)
18. Ciobanu, M.; Heurtault, B.; Schultz, P.; Ruhlmann, C.; Muller, C. D.; Frisch, B. Layersome: development and optimization of stable liposomes as drug delivery system Int. J. Pharm. 2007, 344 (1-2) 154-157 (Pubitemid 47464820)
19. Jain, P.; Jain, S.; Prasad, K. N.; Jain, S. K.; Vyas, S. P. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection Mol. Pharmaceutics 2009, 6 (2) 593-603
20. Szoka, F., Jr; Papahadjopoulos, D. Comparative properties and methods of preparation of lipid vesicles (liposomes) Annu. Rev. Biophys. Biol. 1980, 9 (1) 467-508
21. Vertzoni, M.; Fotaki, N.; Nicolaides, E.; Reppas, C.; Kostewicz, E.; Stippler, E.; Leuner, C.; Dressman, J. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects J. Pharm. Pharmacol. 2004, 56 (4) 453-462 (Pubitemid 38455610)
22. Upadhyay, K. K.; Bhatt, A. N.; Mishra, A. K.; Dwarakanath, B. S.; Jain, S.; Schatz, C.; Le Meins, J. F.; Farooque, A.; Chandraiah, G.; Jain, A. K. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly ([gamma]-benzyl l -glutamate)- b -hyaluronan polymersomes Biomaterials 2010, 31 (10) 2882-2892
23. Jain, A. K.; Swarnakar, N. K.; Godugu, C.; Singh, R. P.; Jain, S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen Biomaterials 2011, 32 (2) 503-515
24. Lee, S. C.; Lee, K. E.; Kim, J. J.; Lim, S. H. The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol J. Liposome Res. 2005, 15 (3-4) 157-166
25. Rowland, R. N.; Woodley, J. F. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase Biochim. Biophys. Acta Lipids Lipid Metab. 1980, 620 (3) 400-409
26. Janssen, M. J. H.; Crommelin, D. J. A.; Storm, G.; Hulshoff, A. Doxorubicin decomposition on storage. Effect of pH, type of buffer and liposome encapsulation Int. J. Pharm. 1985, 23 (1) 1-11 (Pubitemid 15159577)
27. Rudra, A.; Deepa, R. M.; Ghosh, M. K.; Ghosh, S.; Mukherjee, B. Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats Int. J. Nanomed. 2010, 5, 811-823